Valneva (VALN) to Release Quarterly Earnings on Thursday

Valneva (NASDAQ:VALN) is scheduled to release its earnings data before the market opens on Thursday, November 7th. Analysts expect Valneva to post earnings of ($0.30) per share for the quarter. Valneva has set its FY 2024 guidance at EPS.

Valneva (NASDAQ:VALN) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.02. Valneva had a negative return on equity of 20.01% and a negative net margin of 21.31%. The business had revenue of $40.97 million during the quarter, compared to analyst estimates of $46.83 million.

Valneva Stock Down 1.2 %

VALN stock traded down $0.07 on Tuesday, reaching $5.78. 15,049 shares of the company traded hands, compared to its average volume of 11,666. The firm has a fifty day simple moving average of $6.23 and a 200-day simple moving average of $7.18. The company has a market cap of $469.63 million, a P/E ratio of -11.25 and a beta of 2.17. Valneva has a one year low of $5.40 and a one year high of $14.49. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.63 and a quick ratio of 2.15.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their price target on Valneva from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, October 11th.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.